EPZ5676: Potent and Selective DOT1L Inhibitor for Epigenetic and Leukemia Research

Executive Summary: EPZ5676 (SKU A4166) is a competitive, highly selective inhibitor of DOT1L histone methyltransferase, with an IC₅₀ of 0.8 nM and Ki of 80 pM, substantially exceeding selectivity over other methyltransferases (APExBIO). EPZ5676 blocks H3K79 methylation, downregulating MLL-fusion target genes and exhibiting potent cytotoxicity in acute leukemia cell lines with MLL translocations (Liu et al., 2019). The compound is validated in vivo, where dosing in nude rat MV4-11 xenograft models (35–70 mg/kg/day, IV, 21 days) led to complete tumor regression without significant toxicity. EPZ5676 also attenuates renal fibrosis by suppressing fibroblast activation and epithelial-mesenchymal transition (EMT) pathways. Its physicochemical properties, including solubility and recommended storage, facilitate reliable integration into biochemical and cellular workflows.

Biological Rationale

DOT1L (Disruptor of Telomeric Silencing 1-Like) is the sole enzyme responsible for methylating histone H3 on lysine 79 (H3K79), a modification implicated in gene regulation and oncogenesis (Liu et al., 2019). Aberrant DOT1L activity drives the expression of oncogenic programs, especially in MLL (mixed lineage leukemia)-rearranged leukemias. H3K79 methylation is required for the maintenance of leukemic gene expression in these cells (related article). Inhibition of DOT1L suppresses proliferation and survival of these leukemia cells. DOT1L has also been linked to progression in non-malignant diseases, including renal fibrosis, through its role in fibroblast activation and EMT. Thus, targeting DOT1L offers a dual opportunity for studying both cancer epigenetics and fibrotic disease mechanisms.

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ5676 is a small molecule inhibitor designed to target the S-adenosyl methionine (SAM) binding pocket in DOT1L (APExBIO). It acts as a competitive inhibitor, displacing SAM and inducing a conformational change, thereby exposing a hydrophobic pocket in DOT1L. This prevents methyl transfer to H3K79, resulting in the downregulation of genes dependent on this modification. EPZ5676 demonstrates over 37,000-fold selectivity for DOT1L compared to other methyltransferases, including CARM1, EHMT1/2, EZH1/2, PRMTs, SETD7, SMYD2/3, and WHSC1/1L1. Selectivity arises from both structural complementarity and unique binding interactions within the SAM site. The compound’s high affinity is reflected in its low nanomolar IC₅₀ and picomolar Ki values, providing robust inhibition at minimal concentrations. Cellular assays reveal that EPZ5676 efficiently inhibits H3K79 methylation and reduces proliferation in MLL-rearranged leukemia cell lines within days of exposure (internal article, which focuses on innate immunity; here, we elaborate on direct leukemia cytotoxicity and selectivity).

Evidence & Benchmarks

• EPZ5676 displays an in vitro IC₅₀ of 0.8 nM and a Ki of 80 pM against DOT1L enzymatic activity (APExBIO).
• Demonstrates >37,000-fold selectivity over other histone methyltransferases, including CARM1, EHMT1/2, and PRMTs (APExBIO).
• Inhibits proliferation of MV4-11 acute leukemia cells (MLL-AF4 fusion) with an IC₅₀ of 3.5 nM after 4–7 days of treatment (APExBIO).
• In nude rat MV4-11 xenograft models, intravenous administration (35–70 mg/kg/day, 21 days) leads to complete tumor regression with no significant toxicity or weight loss (APExBIO).
• In murine models of renal fibrosis, EPZ5676 attenuates fibroblast activation, EMT, and fibrosis progression (Liu et al., 2019).
• Suppression of profibrotic signaling (Smad3, EGFR, PDGFR, STAT3, AKT, NF-κB) and preservation of renoprotective factors (PTEN, Klotho, Smad7) observed upon DOT1L inhibition (Liu et al., 2019).

For a biochemical and translational overview, see DOT1L Inhibition at the Frontier: Mechanistic Insights and Translational Guidance. While that article explores immune-related consequences, this dossier emphasizes benchmarks and application parameters.

Applications, Limits & Misconceptions

EPZ5676 is primarily used in:

• Biochemical enzyme inhibition assays targeting DOT1L.
• Cell proliferation assays in MLL-rearranged leukemia (e.g., MV4-11 cell line).
• Epigenetic studies of H3K79 methylation in both malignant and non-malignant settings.
• Preclinical in vivo models of leukemia and fibrosis (Liu et al., 2019).

EPZ5676’s high selectivity enables precise interrogation of DOT1L function without major off-target methyltransferase inhibition. Its robust in vitro and in vivo efficacy makes it a leading tool compound in leukemia research and renal fibrosis models. For deeper context on combination strategies and innate immunity, the article EPZ5676: Advanced Insights into DOT1L Inhibition and Innate Immunity complements this dossier by focusing on synergistic and immunomodulatory dimensions.

Common Pitfalls or Misconceptions

• EPZ5676 is not a pan-methyltransferase inhibitor; it is highly selective for DOT1L and does not meaningfully inhibit CARM1, PRMTs, or EZH2 at relevant concentrations.
• The compound is insoluble in water; DMSO or ethanol (with sonication) is required for reliable stock solution preparation.
• Short-term storage of solutions at room temperature can lead to degradation; stock solutions should be stored at ≤ -20°C and used promptly.
• Not effective for malignancies lacking DOT1L dependency or MLL rearrangements; efficacy in solid tumors is not established.
• Does not reverse existing fibrosis or cancer cell death where DOT1L is not mechanistically implicated.

Workflow Integration & Parameters

EPZ5676 is provided as a solid by APExBIO (SKU A4166). The molecular weight is 562.71 Da. Stock solutions can be prepared at ≥28.15 mg/mL in DMSO or ≥50.3 mg/mL in ethanol with ultrasonic assistance. The compound is insoluble in water. It is recommended to store solids at -20°C and to avoid long-term storage of solutions above -20°C. For biochemical enzyme assays, typical working concentrations range from 0.1 to 100 nM. In cell-based experiments, effective antiproliferative activity is observed at 3.5 nM (MV4-11, IC₅₀). In vivo, dosing regimens have used 35–70 mg/kg/day intravenously for 21 days in rat xenograft models. For detailed protocols and application notes, refer to the EPZ5676 product page. For translational context and practical workflow design, see EPZ5676: Mechanistic Insights and Emerging Applications, which bridges in vitro to in vivo workflows; this dossier provides updated benchmarks and storage guidelines.

Conclusion & Outlook

EPZ5676 is a validated and highly selective DOT1L inhibitor supporting advanced epigenetic, leukemia, and fibrosis research. Its nanomolar potency, in vivo efficacy, and physicochemical stability make it a cornerstone tool for dissecting DOT1L biology. Ongoing research continues to define its translational scope and combination potential in oncology and fibrotic disease models. As with all tool compounds, appropriate controls and storage are essential for reproducible results. For further insights into related mechanistic and translational opportunities, see DOT1L Inhibition as a New Frontier in Epigenetic Cancer Therapy, which offers a broader perspective on innovation in DOT1L-targeted strategies; this dossier focuses narrowly on the EPZ5676 compound, updated storage, and application parameters.